<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672395</url>
  </required_header>
  <id_info>
    <org_study_id>CLO-SCB-2019-003</org_study_id>
    <nct_id>NCT04672395</nct_id>
  </id_info>
  <brief_title>A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19</brief_title>
  <acronym>SCB-2019</acronym>
  <official_title>A Double-Blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clover Biopharmaceuticals AUS Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Coalition for Epidemic Preparedness Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clover Biopharmaceuticals AUS Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy,&#xD;
      immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute&#xD;
      respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine&#xD;
      (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in adult subjects 18 years of&#xD;
      age and above.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the efficacy against COVID-19 and SARS-CoV-2 infection,&#xD;
      immunogenicity, reactogenicity, and safety of AS03-adjuvated SCB-2019 vaccine. The COVID-19&#xD;
      pandemic has resulted in high morbidity and mortality, caused major disruption to healthcare&#xD;
      systems, and has had significant socioeconomic impacts. Currently, only limited treatment&#xD;
      options are available against COVID-19 and accelerated vaccine development is urgently&#xD;
      needed. A safe and effective vaccine for COVID-19 prevention would have significant public&#xD;
      health impact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject will receive 2 doses of their assigned treatment, on Days 1 and 22. The treatment will be administered IM in the deltoid region of the upper arm.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a First Occurrence of Moderate-to-Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)</measure>
    <time_frame>Up to Day 8 (7 days after first dose) and up to Day 29 (7 days after second dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited AEs</measure>
    <time_frame>Up to Day 43 (21 days after each dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Up to Day 389 (1 year after second dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with First Occurrence of Any Laboratory-Confirmed SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with First Occurrence of Any Laboratory-Confirmed Asymptomatic SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of Disease Score of COVID-19 or SARS-CoV-2 Infection Cases Starting 14 Days after Second Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a First Occurrence of COVID-19 of Any Severity, Associated with Hospitalization, Starting 14 Days after Second Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of evidence of prior SARS-CoV-2 Infection</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of risk of severe COVID-19</measure>
    <time_frame>Day 36 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of SCB-2019 or Placebo</measure>
    <time_frame>Day 15 up to Day 389 (1 year after second dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Seroconversion for SARS-CoV-2 Specific nAb</measure>
    <time_frame>Day 22, and Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Seroconversion for of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor</measure>
    <time_frame>Day 22, and Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of SCB-2019 binding antibody</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of SCB-2019 binding antibody</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Seroconversion for SCB-2019 binding antibody</measure>
    <time_frame>Day 22, and Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Trimer-Tag binding antibody</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Trimer-Tag binding antibody</measure>
    <time_frame>Day 1, Day 22, Day 35, Day 205, and Day 389</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS03-adjuvanted SCB-2019 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AS03-adjuvanted SCB-2019 vaccine</intervention_name>
    <description>Group 1: Participants will receive 1 intramuscular (IM) injection of 9 microgram (ug) SCB-2019 with AS03 adjuvant on Day 1 and on Day 22</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo; 0.9% saline</intervention_name>
    <description>Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females ≥18 years of age, inclusive.&#xD;
&#xD;
          2. Participants who are willing and able to comply with study requirements, including all&#xD;
             scheduled visits, vaccinations, laboratory tests, the electronic completion of the&#xD;
             COVID-19 ePRO and other study procedures.&#xD;
&#xD;
          3. Healthy adults or adults with pre-existing medical conditions who are in stable&#xD;
             condition.&#xD;
&#xD;
             A stable medical condition is defined as disease not requiring significant change in&#xD;
             therapy or hospitalization for worsening disease during the 3 months before enrolment&#xD;
&#xD;
          4. Female subjects are eligible to participate in the study if not pregnant, not&#xD;
             breastfeeding, and at least 1 of the following criteria apply:&#xD;
&#xD;
             • Women of childbearing potential (WOCBP) must have a negative urine pregnancy test&#xD;
             prior to each vaccination. A confirmatory serum pregnancy test may be conducted at the&#xD;
             Investigator's discretion. They must be using a highly effective licensed method of&#xD;
             birth control for 30 days prior to the first vaccination and must agree to continue&#xD;
             such precautions during the study until 90 days after the second vaccination.&#xD;
&#xD;
          5. Individuals (or their legally acceptable representative based on local regulations)&#xD;
             willing and able to give an informed consent, prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with laboratory-confirmed SARS-CoV-2 infection (e.g., a positive result&#xD;
             for the Rapid COVID-19 antigen test) or a known history of SARS-CoV-2 infection.&#xD;
&#xD;
          2. Individuals with behavioral or cognitive impairment (including drug and alcohol abuse)&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
          3. Individuals with any progressive or severe neurologic disorder, seizure disorder, or&#xD;
             history of Guillian-Barré syndrome.&#xD;
&#xD;
          4. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic&#xD;
             agents or systemic corticosteroids, e.g., for cancer or an autoimmune disease, or&#xD;
             planned receipt during the study period.&#xD;
&#xD;
          5. Individuals who are pregnant, or breastfeeding, or planning to become pregnant during&#xD;
             the study period.&#xD;
&#xD;
          6. Individuals who have a history of severe adverse reaction associated with a vaccine or&#xD;
             severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccine&#xD;
&#xD;
          7. Individuals who have a history of malignancy within 1 year before screening&#xD;
&#xD;
          8. Individuals who have received any other investigational product within 30 days prior&#xD;
             to Day 1 or intent to participate in another clinical study at any time during the&#xD;
             conduct of this study.&#xD;
&#xD;
          9. Individuals who have received previous vaccination with any coronavirus vaccine.&#xD;
&#xD;
         10. Individuals who have received any other licensed vaccines within 28 days prior to&#xD;
             enrollment in this study or who are planning to receive any vaccine up to 14 days&#xD;
             after the second vaccination.&#xD;
&#xD;
         11. Individuals with known bleeding disorder that would, in the opinion of the&#xD;
             investigator, contraindicate intramuscular injection.&#xD;
&#xD;
         12. Individuals who received any blood/plasma products or immunoglobulins within 60 days&#xD;
             prior to Day 1 or plan to receive it during the study period.&#xD;
&#xD;
         13. Individuals with any condition that, in the opinion of the Investigator, may increase&#xD;
             the risk of study participation or interfere with the assessment of the primary study&#xD;
             objectives&#xD;
&#xD;
         14. Individuals with fever &gt;37.8°C (≥100.04°F; irrespective of method), or any acute&#xD;
             illness at baseline (Day 1) or within 3 days of randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Smolenov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clover Biopharmaceuticals AUS Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Mwangi, MD</last_name>
    <phone>+1 847-691-8580</phone>
    <email>Vincent.mwangi@cloverbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pilar Rubio, MD</last_name>
    <phone>+57 314-857-0960</phone>
    <email>Pilar.Rubio@cloverbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anima</name>
      <address>
        <city>Alken</city>
        <zip>3570</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Linde Buntinx, Ph.D</last_name>
      <phone>+3211316528</phone>
      <email>linde.buntinx@anima-alken.be</email>
    </contact>
    <contact_backup>
      <last_name>Hilde Bollen, M.D</last_name>
      <phone>+3211316271</phone>
      <email>hilde.bollen@anima-alken.be</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Hilde Bollen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabel Leroux-Roels, M.D</last_name>
      <phone>+3293323328</phone>
      <email>isabel.lerouxroels@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Maes</last_name>
      <phone>+3293329465</phone>
      <email>cathy.maes@uzgent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Isabel Leroux-Roels, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice RESPISOM Namur</name>
      <address>
        <city>Namur</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Benoît Martinot, M.D</last_name>
      <phone>+32495502608</phone>
      <email>martinot.j@scarlet.be</email>
    </contact>
    <contact_backup>
      <last_name>Johan Silliard</last_name>
      <phone>+32495823443</phone>
      <email>johan.silliard@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Jean Benoît Martinot, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto D'OR de Pesquisa e Ensino</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>Rio Do Janeiro</state>
        <zip>22281-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Cerbino Neto, MBBS</last_name>
      <phone>+552125375910</phone>
      <email>natalia.salvador@idor.org</email>
    </contact>
    <investigator>
      <last_name>Dr. Jose Cerbino Neto, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Atena de Pesquisa Clinica</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59020-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Maria Sanali Oliveira Paiva, M.D, Ph.D</last_name>
      <phone>+558420203430</phone>
      <email>msanali@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>HUGO DIÓGENES DE O. PAIVA, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Maria Sanali Oliveira Paiva, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPCLIN - Centro de Pesquisas Clínicas de Natal</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Kleber Giovanni Luz, M.D</last_name>
      <phone>+558432098200</phone>
      <email>klebergluz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Kleber Giovanni Luz, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Eduardo Sprinz</last_name>
      <phone>+555133596326</phone>
      <email>esprinz@hcpa.edu.br</email>
    </contact>
    <contact_backup>
      <last_name>Thainá Garbino dos Santos</last_name>
      <phone>+555133596368</phone>
      <email>thaisantos@hcpa.edu.br</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Eduardo Sprinz, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital da Universidade Federal de Santa Maria CEP/UFSM</name>
      <address>
        <city>Santa Maria</city>
        <state>Rio Grande Do Sul</state>
        <zip>97105-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Bogotá D.C.</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <zip>1100118641</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Diana Huertas</last_name>
      <phone>+573153248635</phone>
      <email>leonardo.bautista@caimed.com</email>
    </contact>
    <contact_backup>
      <last_name>Lizeth Flórez</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Leonardo Bautista Toloza, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Acacías</name>
      <address>
        <city>Acacías</city>
        <zip>507001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Niny Bolivar</last_name>
      <phone>+5786560160</phone>
      <email>hhvelas@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Leydi Lozano</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Hector Hernan Velasquez Zapata, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica de la Costa Ltda.</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Alexandra Castañeda, M.Sc</last_name>
      <phone>+5753736200</phone>
      <email>lbrochado@clinicadelacosta.co</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Higgins Molina, Physician</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Leonardo Fabio Brochado Fontaivo, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S.</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Hilda Giraldo Orjuela</last_name>
      <phone>+5724860220X1113</phone>
      <email>pio.lopez@ceiponline.org</email>
    </contact>
    <contact_backup>
      <last_name>Julio Cesar Rengifo</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Pio Lopez, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Aguazul</name>
      <address>
        <city>Casanare</city>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Margarita Barón</last_name>
      <phone>+57186383737</phone>
      <email>edith.rodriguez@caimed.com</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Abella</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Edith Johana Rodriguez Arenales, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Yopal</name>
      <address>
        <city>Yopal</city>
        <zip>850001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Lina Arias</last_name>
      <phone>+5786340000</phone>
      <email>tatiana.medina@caimed.com</email>
    </contact>
    <contact_backup>
      <last_name>Yessica Gutiérrez</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Myriam Tatiana Medina Bernal, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Sanitario de Santo Domingo (Satellite Site)</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10201</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. William Joa, M.D</last_name>
      <phone>+8092216694</phone>
      <email>lrp@claro.net.do</email>
    </contact>
    <contact_backup>
      <last_name>Laura Rivera</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Luis Maria Rivera Mejia, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Maternidad Nuestra Senora de la Altagracia.</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10201</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. William Joa, M.D</last_name>
      <phone>+8092216694</phone>
      <email>lrp@claro.net.do</email>
    </contact>
    <contact_backup>
      <last_name>Laura Rivera</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Luis Maria Rivera Mejia, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Würzburg Mitte gGmbH - Standort Juliusspital</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Tino Schwarz, M.D</last_name>
      <phone>+499313932260</phone>
      <email>t.schwarz@kwm-klinikum.de</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Mathias Mäurer, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Tino Schwarz, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Oliver Kornmann, M.D</last_name>
      <phone>+4969695972580</phone>
      <email>kornmann@ikf-pneumologie.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Eich, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Marc Oliver Kornmann, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland Pfalz</state>
        <zip>55128</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephanie Korn, M.D</last_name>
      <phone>+4961313336345</phone>
      <email>korn@ikf-pneumologie.de</email>
    </contact>
    <investigator>
      <last_name>Dr. Stephanie Korn, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berliner Centrum f. Reise- und Tropenmedizin (BCRT)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Tomas Jelinek, M.D</last_name>
      <phone>+493096060940</phone>
      <email>jelinek@bcrt.de</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Elliger, M.Sc.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Tomas Jelinek, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Medicine</name>
      <address>
        <city>Maharajgunj</city>
        <state>Kathmandu</state>
        <zip>44613</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <contact>
      <last_name>Ms. Anita Shrestha, B.Sc.</last_name>
      <phone>+977 - 9813930507</phone>
      <email>anitashrestha839@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Laxman Shrestha, MD</last_name>
      <phone>+977- 9851036550</phone>
      <email>laxmanshree12@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Laxman Shrestha, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dhulikhel Hospital</name>
      <address>
        <city>Dhulikhel</city>
        <zip>45210</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Pranodan Poudel, MBBS</last_name>
      <phone>+977 - 9867159282</phone>
      <email>pranodan.poudel@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Amit Khadgi, MD</last_name>
      <phone>+977 - 9818420526</phone>
    </contact_backup>
    <investigator>
      <last_name>Dr. Dipesh Tamrakar, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cevaxin David</name>
      <address>
        <city>David</city>
        <state>Doleguita</state>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Patiño, Ph.D</last_name>
      <phone>+50762059692</phone>
      <email>erife23@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Gabriel Rebollon, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Ericka Ferguson, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cevaxin 24 de diciembre</name>
      <address>
        <city>Ciudad de Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Milagros Chan, MD</last_name>
      <phone>+50766742552</phone>
      <email>rchandlern@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Gabriel Rebollon</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Reynaldo Chandler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cevaxin Panama Clinic</name>
      <address>
        <city>Ciudad de Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Morgan Hess</last_name>
      <phone>+50766758713</phone>
      <email>magda3377@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Gabriel Rebollon, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Magda Rojas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEVAXIN Chorrera</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergio Ruiz, M.Sc</last_name>
      <phone>+50766738779</phone>
      <email>pbarrerap@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Gabriel Rebollon, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Paulo Barrera, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia INDICASAT</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Digna Wong</last_name>
      <phone>+5075170752</phone>
      <email>dwong@indicasat.org.pa</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Aldazoro, Physician</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Celio Ríos, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cevaxin Av Mexico</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Gabriel Rebollon</last_name>
      <phone>+5075129808ext174</phone>
      <email>xsaezll@cwpanama.net</email>
    </contact>
    <contact_backup>
      <last_name>Sergio Ruiz</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Xavier Saez Llorens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>De La Salle Medical and Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Charles Yu, M.D</last_name>
      <phone>+63464818000</phone>
      <email>chrlsyu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Andres Luis Agoncillio, M.D</last_name>
      <email>agoncillo_andre@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Charles Yu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Pinas Doctors Hospital</name>
      <address>
        <city>Las Piñas</city>
        <zip>1742</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Mari Rose De los Reyes, M.D</last_name>
      <phone>+6328620162</phone>
      <email>jimrose06@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Mari Rose De Los Reyes, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tropical Disease Foundation</name>
      <address>
        <city>Makati</city>
        <zip>1230</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Rolando Achivar</last_name>
      <phone>+639185250881</phone>
      <email>bhirach_1chivar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Edison Alberto, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manila Doctors Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Camilo Roa, M.D</last_name>
      <phone>+6325266922</phone>
      <email>camiloroa@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Camilo Roa, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of the Philippines Manila - College of Public Health</name>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Lulu Bravo, M.D</last_name>
      <phone>+6325218450</phone>
      <email>lulubravo@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Ylade</last_name>
      <email>mcylade@up.edu.ph</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Lulu Bravo, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asian Hospital and Medical Center</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>r. Charissa Fay Corazon Borja-Tabora, M.D</last_name>
      <phone>+6328098867</phone>
      <email>cbtabora@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jemelyn Garcia, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Charissa Fay Corazon Borja-Tabora, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UERM Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Josefina Carlos, M.D</last_name>
      <phone>+6327150796</phone>
      <email>janemendoza64@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ma. Aleta Paula B. Delfin, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Josefina Carlos, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of the East Ramon Magsaysay Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Milagros Bautista, M.D</last_name>
      <phone>+6329252401</phone>
      <email>milamd_2000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Milagros Bautista, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FEU-NRMF Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1118</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. May Montellano, M.D</last_name>
      <phone>+6327355341</phone>
      <email>clavejethrmaymd16@gmail.commt@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Cerelyn Dacula, M.D</last_name>
      <email>ced_md_52978@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. May Montellano, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Taguig</city>
        <zip>1634</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Mario Panaligan, M.D</last_name>
      <phone>+6327154061</phone>
      <email>alvinkarlleonardo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gelza Mae Zabat, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Mario Panaligan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Lublin II</name>
      <address>
        <city>Lublin</city>
        <zip>20-555</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Katarzyna Zelazowska, M.D</last_name>
      <phone>+48814402474</phone>
      <email>katarzyna.zelazowska@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Dr. Katarzyna Zelazowska, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Pulawy</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Marek Konieczny, M.D, Ph.D</last_name>
      <phone>+48818886333</phone>
      <email>izabela.szczebiot@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Dr. Marek Konieczny, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-326</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Michał Mazur, M.D</last_name>
      <phone>+48501427278</phone>
      <email>s.mazur@medyk.rzeszow.pl</email>
    </contact>
    <contact_backup>
      <last_name>Justyna Bytnar, M.A</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Stanislaw Mazur, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skórzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Michal Kwiatek, M.D</last_name>
      <phone>+48793602210</phone>
      <email>m.kwiatek@examen.pl</email>
    </contact>
    <contact_backup>
      <last_name>Lukasz Pruchniewski, M.D</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Michal Kwiatek, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Staszow</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Katarzyna Wawrzyniec, Ph.D</last_name>
      <phone>+48158641234</phone>
      <email>katarzyna.wawrzyniec@komed-ck.pl</email>
    </contact>
    <contact_backup>
      <last_name>Iwona Pawlik</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Katarzyna Wawrzyniec, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Luiza Jonczak, M.D, Ph.D</last_name>
      <phone>+48223702134</phone>
      <email>l.jonczak@etg-network.com</email>
    </contact>
    <contact_backup>
      <last_name>Piotr Furman, M.A</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dr. Luiza Jonczak, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Aysha Badat, MB.ChB</last_name>
      <phone>+27119836501</phone>
      <email>abadat@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Dr. Aysha Badat, MB.ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DJW Research</name>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Jaco Jurgens, MB.ChB</last_name>
      <phone>+27119541021</phone>
      <email>jacojuhl@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Vermooten, B.Sc</last_name>
      <phone>+27116606683</phone>
      <email>zvermooten@mweb.co.za</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Jaco Jurgens, MB.ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soweto Clinical Trials Centre</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Qasim Bhorat, MB.ChB</last_name>
      <phone>+27119844417</phone>
      <email>qeb@sowetoctc.co.za</email>
    </contact>
    <investigator>
      <last_name>Dr. Qasim Bhorat, MB.ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr JM Engelbrecht Trial Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Johannes Engelbrecht, M.Med</last_name>
      <phone>+27218407012</phone>
      <email>engelbrecht@samedical.co.za</email>
    </contact>
    <investigator>
      <last_name>Dr. Johannes Engelbrecht, M.Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Dominican Republic</country>
    <country>Germany</country>
    <country>Nepal</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, Liang JG, Shore G, Wang X, Liang P. Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. Sci Rep. 2017 Aug 21;7(1):8953. doi: 10.1038/s41598-017-09518-1. Erratum in: Sci Rep. 2018 Mar 22;8(1):5266.</citation>
    <PMID>28827692</PMID>
  </reference>
  <reference>
    <citation>Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007 Aug 1;25(31):5675-84. Epub 2007 Mar 12.</citation>
    <PMID>17448577</PMID>
  </reference>
  <reference>
    <citation>Rhodes SJ, Knight GM, Kirschner DE, White RG, Evans TG. Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling. J Theor Biol. 2019 Mar 21;465:51-55. doi: 10.1016/j.jtbi.2019.01.017. Epub 2019 Jan 10.</citation>
    <PMID>30639297</PMID>
  </reference>
  <reference>
    <citation>Food and Drug Administration letter. Device: BinaxNOW COVID-19 Ag Card. 26 August 2020. https://www.fda.gov/media/141567/download. Accessed on 15 September 2020.</citation>
  </reference>
  <reference>
    <citation>Food and Drug Administration Guidance Document: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at https://www.fda.gov/media/73679/download. Accessed on 15 September 2020.</citation>
  </reference>
  <reference>
    <citation>Safety Platform for Emergency vACcines (SPEAC). D2.3 Priority List of Adverse Events of Special Interest: COVID-19. V1.1 Date 05 March 2020. https://media.tghn.org/articles/COVID-19_AESIs_SPEAC_V1.1_5Mar2020.pdf. Accessed on 15 September 2020.</citation>
  </reference>
  <reference>
    <citation>Chan ISF, Bohidar NR (1998) Exact power and sample size for vaccine efficacy studies, Communications in Statistics - Theory and Methods 1998;27(6):1305-22.</citation>
  </reference>
  <reference>
    <citation>Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res 2013;5(4):311-20.</citation>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

